Evidence map›Paper›PMID 41461997›Full record

ReviewAdvances in therapy2026

Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations.

Bryan L Peacker, Jonathan C Hwang, Rebecca I Hartman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bryan L Peacker *Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3347-0629
Jonathan C Hwang *University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Rebecca I HartmanHarvard Medical School, Boston, MA, USA. rhartman@bwh.harvard.edu.ORCID 0000-0002-1960-3296

Funding

U.S. Department of Defense W81XWH2110819U.S. Department of Veterans Affairs VA CSR&D IK2 CX-002531
6 · The paper itself

Abstract

While immunotherapy has been widely adopted for the treatment of melanoma, its application in patients with complex comorbidities remains challenging. This review explores evidence on the efficacy, safety, and special considerations for the use of immunotherapy in patients with altered immune systems, including patients with human immunodeficiency virus (HIV), tuberculosis, solid organ or hematopoietic cell transplantation, autoimmune diseases, and pregnant women. Despite data emphasizing the feasibility of immunotherapy treatment in these populations, standardized management algorithms are lacking. Future research should consider either including these patients in prospective trials or attempting to collect data via registries to provide more clarity on the management of immunologically vulnerable patients with melanoma.

Indexed as

ImmunotherapyMelanomaSkin NeoplasmsAutoimmune DiseasesFemaleHIV InfectionsHumansPregnancyAltered immune systemsAutoimmune diseasesHIVImmune checkpoint inhibitorsImmunotherapyMelanoma treatmentPregnancySpecial populationsTransplantationTuberculosis

Identifiers

PMID41461997
PMCPMC12909377

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.